# A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma

> **NCT04007198** · PHASE1 · COMPLETED · sponsor: **Equillium** · enrollment: 18 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** EQ001
- **DRUG:** EQ001 Placebo

## Key facts

- **NCT ID:** NCT04007198
- **Lead sponsor:** Equillium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-20
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007198, "A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04007198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*